AI-Driven Neoantigen Discovery & TCR Screening
Our integrated computational and experimental framework is designed to accelerate target discovery and validation for next-generation T cell-based immunotherapies. By combining AI-driven analytics with advanced screening technologies, we enable the rapid identification of clinically relevant antigens and TCR candidates for personalized and off-the-shelf therapeutic development.
AI-Based Neoantigen Prediction Platform
Proprietary pMHC binding prediction and immunogenicity scoring
Patient-specific neoantigen pipelines integrated with NGS
TCR Library Screening
High-throughput TCR sequencing and epitope mapping
TCR-pMHC binding assays and cytotoxicity validation
Functional Validation of TCR Candidates
TCR-engineered T cell generation and tumor killing assays
In vivo validation using humanized or syngeneic mouse models